A
0.829
0.01 (1.10%)
| Previous Close | 0.820 |
| Open | 0.875 |
| Volume | 21,362 |
| Avg. Volume (3M) | 73,710 |
| Market Cap | 5,797,891 |
| Price / Book | 0.420 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -2,514.78% |
| Diluted EPS (TTM) | -2.34 |
| Quarterly Revenue Growth (YOY) | -57.30% |
| Current Ratio (MRQ) | 5.90 |
| Operating Cash Flow (TTM) | -13.25 M |
| Levered Free Cash Flow (TTM) | -8.46 M |
| Return on Assets (TTM) | -35.70% |
| Return on Equity (TTM) | -59.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aprea Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.90% |
| % Held by Institutions | 40.94% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Wedbush, 744.39%) | Buy |
| Median | 5.50 (563.45%) | |
| Low | 4.00 (HC Wainwright & Co., 382.51%) | Buy |
| Average | 5.50 (563.45%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.625 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 10 Feb 2026 | 7.00 (744.39%) | Buy | 0.660 |
| HC Wainwright & Co. | 29 Jan 2026 | 4.00 (382.51%) | Buy | 0.590 |
| 18 Dec 2025 | 5.00 (503.14%) | Buy | 0.910 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor |
| 29 Jan 2026 | Announcement | Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan |
| 29 Jan 2026 | Announcement | Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 18 Dec 2025 | Announcement | Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 |
| 09 Dec 2025 | Announcement | Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 12 Nov 2025 | Announcement | Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |